In Responder specimens, the number of ICAM‐1‐positive tumor cells decreased dose‐dependently with both lidocaine and ropivacaine (mean ± SD for lidocaine 1 μm: 62 ± 37% of control, 10 μm: 35 ± 26%; ropivacaine 1 μm: 75 ± 61%, 10 μm: 59 ± 38%, Figure 8Ai). Here, ICAM1 is linked to neoplasm.